Margetuximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Margetuximab
Monoclonal antibody
Type ?
Source Chimeric (mouse/human)
Target ch4D5[citation needed]
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6484H10010N1726O2024S42
Molar mass 145.9 kg/mol

Margetuximab is a chimeric IgG monoclonal antibody against HER2 designed for the treatment of cancer.[1][2]

This drug was created by Raven biotechnologies, which was later acquired by MacroGenics. It was engineered to increase affinity for CD16A polymorphisms and decrease affinity for FcγRIIB (CD16B), an inhibitory receptor.[3]

It binds to the same target (epitope) as trastuzumab,[4] on the HER2 receptor.

It is currently in phase 3 clinical trials for combination therapy in metastatic breast cancer[5] in collaboration with Merck.[6] Phase II trials are also in progress for gastric cancer and esophageal cancer.[7]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Margetuximab, American Medical Association.
  2. ^ https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=681010
  3. ^ "Margetuximab". AdisInsight. Retrieved 1 February 2017. 
  4. ^ Pegram Discusses Promise of Margetuximab/Chemo Combo for HER2+ Breast Cancer. Jan 2017
  5. ^ https://clinicaltrials.gov/ct2/show/NCT02492711
  6. ^ http://www.mercknewsroom.com/news-release/prescription-medicine-news/macrogenics-and-merck-collaborate-immuno-oncology-study-eval
  7. ^ https://clinicaltrials.gov/ct2/show/NCT02689284